Imeik Technology Development Co.,Ltd.
300896
Rangering i aksjer
#3836
Imeik Technology Development Co.,Ltd. specializes in the research, development,... Imeik Technology Development Co.,Ltd. specializes in the research, development, manufacturing, and distribution of biomedical materials. The company's diverse product portfolio caters to both the medical aesthetics field and general skincare needs. Within its medical beauty offerings, Imeik provides a range of recognized brands including Moisten Angel, IFRESH, Yimei, Hearty, Bonita Bonita, and Tightly. Additionally, its comprehensive skincare line features hydrating lotions, anti-aging and firming serums, concentrated essence creams, revitalizing facial masks, restorative chitosan B5 sprays, and clarifying and illuminating liquids. Established in 2004, the company's operations are based in Beijing, China.
Aksjekurs
$14.36
Markedsverdi
$4.35B
Endring (1 dag)
0.22%
Endring (1 år)
-39.05%
Land
CN
Handel Imeik Technology Development Co.,Ltd. (300896)
Kategori
Healthcare
P/B-forhold for Imeik Technology Development Co.,Ltd. (300896)
P/B-forhold per October 2026 TTM: 3.60
Ifølge Imeik Technology Development Co.,Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 3.60. Ved slutten av 2023 hadde selskapet et P/B-forhold på 9.74.
P/B-historikk for Imeik Technology Development Co.,Ltd. fra 2014 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 3.60 | -48.89% |
| 2024 | 7.05 | -27.60% |
| 2023 | 9.74 | -34.97% |
| 2022 | 14.97 | -9.12% |
| 2021 | 16.47 | 32.81% |
| 2020 | 12.40 | -72.01% |
| 2019 | 44.31 | -18.96% |
| 2018 | 54.68 | -18.99% |
| 2017 | 67.50 | -15.17% |
| 2016 | 79.56 | -42.30% |
| 2015 | 137.90 | -41.94% |
| 2014 | 237.50 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 8.1997 | 127.55% |
US
|
|
| 1.7417 | -51.67% |
FR
|
|
| - | - |
JP
|
|
| 2.1258 | -41.01% |
US
|
|
| - | - |
CH
|
